Clinical trial · Observational
DNA Analysis of Bone Marrow and Blood Samples From Young Patients With Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
The Molecular Epidemiology of de Novo and Treatment Related 11q23 Leukemia in the Young
NCT00899652CI-TRIAL-00027224completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Studying samples of bone marrow and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is looking at DNA in bone marrow and blood samples from young patients with acute myeloid leukemia or acute lymphoblastic leukemia.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| chromosomal translocation analysis | Genetic | — | UNRESOLVED |
| cytogenetic analysis | Genetic | — | UNRESOLVED |
| gene rearrangement analysis | Genetic | — | UNRESOLVED |
| mutation analysis | Genetic | — | UNRESOLVED |
| Southern blotting | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- All Patients
- description
- Completion of Telephone Study Entry Form, Additional On Study Form, and Specimen Transmittal Form.
- interventionNames
- Genetic: Southern blotting
- Genetic: chromosomal translocation analysis
- Genetic: cytogenetic analysis
- Genetic: gene rearrangement analysis
- Genetic: mutation analysis
Primary outcomes (2)
- measure
- Clinical, morphologic, immunologic, cytogenetic, and molecular characteristics of acute lymphoblastic leukemia and de novo and secondary acute myeloid leukemia (AML)
- measure
- Comparison of secondary AML vs de novo AML at the level of Southern blot, breakpoint sequence, and DNA topoisomerase II cleavage sites
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 21 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of leukemia meeting 1 of the following criteria: * Acute lymphoblastic leukemia OR acute myeloid leukemia (AML) (\< 1 year of age at diagnosis) * M4 OR M5 AML (\< 5 years of age at diagnosis) * Secondary leukemia (\< 21 years of age at diagnosis) * Bone marrow sample, peripheral blood (WBC \> 10,000/mm³ and 20% peripheral blasts), or pheresis bag available PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified
References
Publications (0)
Data not yet available
No reference posted for this study.